María Dolores López Carmona
Medicina Interna. UGC. Hospital Universitario Regional de Málaga.
CAREER SUMMARY
Specialist in cardiovascular disease and its factors, I did my doctoral thesis in translational research, on the development of atherosclerosis. I am currently developing my healthcare activity in the field of vascular medicine, being since 2015, holder of a monographic consultation of peripheral arterial disease and conducting clinical research in that field. I am part of multidisciplinary working groups to address atherosclerotic disease in complex clinical situations such as in the context of chronic infections or neoplasms. This consultation is integrated into a multidisciplinary unit with Cardiovascular Surgery and Interventional Radiology. My activity combines clinical assistance, clinical and translational research and scientific dissemination
ACADEMIC TRAINING
Bachelor / Degree / Doctorate / University / Year
Graduate in medicine and surgery Universidad de Extremadura 2001
Training Stay Institut Cataá de Ciences Cardiovasculares Barcelona / Predoctoral /2017
Doctorate in Internal Medicina Programm Universidad de Málaga 2011
Postgraduate Degrees:
“Metodología de la investigación clínica”/ Universitat de Barcelona /2016
“ Diabetes en la práctica clínica diaria/” Universitat de Barcelona/ 2017
WORK EXPERIENCE
RESERACH EXPERIENCE Employing entity : Servicio Andaluz de Salud.
Center Hospital Regional de Málaga
Tipo de entidad: Agencia Estatal
Categoría profesional: Facultativo Especialista de Area en Medicina Interna
Fecha de inicio: 20/06/2008- current
Modalidad de contrato: Interino Tiempo completo
Member of Iinstituto para la investigación biomédica de Málaga (IBIMA) and Fundación publica andaluza para la investigación en Málaga en biomedicina y salud. (FIMABIS)
Public financing projects
1-Early Prevention of Diabetes Complications in people with Hyperglycaemia in Europe: Study e-PREDICE Union Europea HEALTH.2011.2.4.3-1: Investigator-driven clinical trials to reduce diabetes complications. FP7-HEALTH-2011-two-stage. (EVIDEM Consultores). Jaakko Tuomilehto. 2014-2018. 200.870,2 €.
2.-Efecto de la Intervención en el Estilo de Vida en el Desarrollo de Nefropatía Diabética en Pacientes Con Prediabetes Sin Evidencia de Lesión Micro/macrovascular Consejería de Salud de la Junta de Andalucía. (Fundación publica andaluza para la investigación en Malaga en biomedicina y salud).
Private projects and clinical trials
1. Biolux P-III Spain . “Un registro prospectivo, nacional, multicéntrico, poscomercialización para evaluar el rendimiento clínico del catéter balón liberador Passeo-18 Lux en lesiones de la arteria femoropoplítea larga – III ESPAÑA Maria Dolores Lopez Carmons. Desde 17/11/2018
2 A 4-week, randomised double-blinded study to evaluate the efficacy of Glucose-Fructose Syrup: Natural sugar syrup (product of Manuka honey) versus Sugar Syrup on blood-lipids in healthy hypercholesterolaemic (total cholesterol ≥6.2 mmol/L) adults Antonina Starodubova. (ManukaMed LP). Desde 27/01/2018.
3 : Implementación de una herramienta para la desprescripción de medicamentos en pacientes pluripatológicos polimedicados. Ensayo clínico DESPRES Ricardo Gómez Huelgas. Desde 15/09/2017.
4 A phase III, multicenter, randomized, assessor-blind, parallel group, controlled study to evaluate efficacy and safety of Granulox® as an adjunct to standard of care in treating subjects with diabetic foot ulcer Ricardo Gómez Hulegas. Desde 30/05/2017.
5 CARacTerizAción del riesGO de Trombosis en pacientes con cáncer. Estudio CARTAGO Ricardo Gómez Huelgas. Desde 23/02/2017.
6 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin Compared to Placebo in Subjects with Symptomatic Atherosclerotic CV Disease and Prediabetes on CV Outcomes and the Development of T2DMA Ricardo Gómez Huelgas. Desde 13/06/2016.
7 A phase 3, randomized, double-blind, active-controlled study to evaluate the effects of Bexaglifozin vs Glimepiride in subjects with Type 2 Diabetes Mellitus who haves inadequate glycemic control by metformin. Theracos Sub, LLC. Ricardo Gómez Huelgas. Desde 17/05/2016.
8 A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin versus Glimepiride in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin Ricardo Gómez Huelgas. Desde 02/05/2016.
9 Estudio fase IV para evaluar la eficacia y seguridad de la nueva insulina Glargina 300 U/mL (GLA-300) durante la hospitalización y la intensificación al alta en pacientes con diabetes tipo 2. Estudio COBALTA Ricardo Gómez Huelgas. Desde 18/01/2016.
10 Estudio a largo plazo, aleatorizado, doble ciego, controlado con placebo para determinar el efecto de Albiglutida, cuando se añade al tratamiento hipoglucemiante estándar, sobre eventos cardiovasculares mayores en pacientes con Diabetes Mellitus Tipo 2. GLAXOSMITHKLLINE (GSK). Ricardo Gómez Huelgas. Desde 30/10/2015.
11 Albiglutida + insulina glargina frente a insulina lispro + insulina glargina en el tratamiento de sujetos con diabetes mellitus de tipo 2: Estudio Switch GLAXOSMITHKLLINE (GSK). Ricardo Gómez Huelgas. Desde 19/10/2015.
12 Ensayo clínico controlado y aleatorizado, en el que se compara la seguridad y la eficacia de la liraglutida frente a la insulina glargina en el tratamiento de pacientes con diabetes de tipo 2, tras recibir el alta hospitalaria Emory University School of Medicine.. Ricardo Gómez Huelgas. Desde 07/01/2015.
Publications
Carrasco-Sánchez FJ, López-Carmona MD, Martínez-Marcos FJ, Pérez-Belmonte LM, Hidalgo-Jiménez A, Buonaiuto V, Suárez Fernández C, Freire Castro SJ, Luordo D, Pesqueira Fontan PM, Blázquez Encinar JC, Magallanes Gamboa JO, de la Peña Fernández A, Torres Peña JD, Fernández Solà J, Napal Lecumberri JJ, Amorós Martínez F, Guisado Espartero ME, Jorge Ripper C, Gómez Méndez R, Vicente López N, Román Bernal B, Rojano Rivero MG, Ramos Rincón JM, Gómez Huelgas R; SEMI- COVID-19 Network. Admission hyperglycemiaas a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: Data from the Spanish SEMI-COVID-19 Registry. Ann Med. 2020 Oct 16:1-22. doi: 0.1080/07853890.2020.1836566.
Narankiewicz D, Ruiz-Nava J, Buonaiuto V, Ruiz-Moreno MI, López-Carmona MD, Pérez-Belmonte LM, Gómez-Huelgas R, Bernal-López MR. Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population. Int J Environ Res Public Health. 2020 May 18;17(10):3518. doi: 10.3390/ijerph17103518. PMID: 32443453; PMCID: PMC7277926.
Pérez-Belmonte LM, López-Carmona MD, Quevedo-Marín JL, Ricci M, Martín-Carmona J, Sanz-Cánovas J, López-Sampalo A, Martín-Escalante MD, Bernal-López MR, Gómez-Huelgas R. Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. Int J Environ Res Public Health. 2020 Sep 19;17(18):6845. doi: 10.3390/ijerph17186845
Ruiz-Moreno MI, Vilches-Perez A, Gallardo-Escribano C, Vargas-Candela A, Lopez-Carmona MD, Pérez-Belmonte LM, Ruiz-Moreno A, Gomez-Huelgas R, Bernal- Lopez MR. Metabolically Healthy Obesity: Presence of Arterial Stiffness in the Prepubescent Population. Int J Environ Res Public Health. 2020 Sep 24;17(19):6995. doi: 10.3390/ijerph17196995
Pérez-Belmonte LM; et al. (11/4). 2019. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study ANN MED. 51-3-4, pp.251-262.Gómez-Huelgas R; et al. (10/3). 2019. Trends in Diabetes-Related Potentially Preventable Hospitalizations in Adult Population in Spain, 1997⁻2015: A Nation-Wide Population-Based Study.J CLIN MED. 8-4.
Lara-Rojas CM; et al. (6/3). 2018. National trends in diabetes mellitus hospitalization in Spain 1997-2010: Analysis of over 5.4 millions of admissions EUR J INTERN MED. 60, pp.83-89.
López-Carmona MD; et al. (6/1). 2017. CD36 overexpression: a possible etiopathogenic mechanism of atherosclerosis in patients with prediabetes and diabetes. DIABETOL METAB SYNDR. 9-55.
Pérez-Belmonte LM; et al. (6/3). 2017. National Trends in Heart Failure Hospitalization Rates in Patients With Diabetes Mellitus: 1997-2010 REV ESP CARDIOL. 71-5, pp.408-410.
Gómez -Huelgas R; Lopez-Carmona MD. (2/2). 2017. Diabetes in the elderly: primum non nocere. REV CLIN ESP. 217-9, pp.518-519.
Perez-Belmonte LM; et al. (10/4). 2018. Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study) J CLIN MED. 11-7.
Caballero Martinez LF; Cobos -Palacios L; Lopez-Carmona MD*. 2017. Medicine: 12 Protocolos de práctica asistencial Protocolo diagnóstico y cuantificación de los factores de riesgo cardiovascular. 12-42, pp.2509-2515.
Lara Rojas, CM.; et al. 2015. Familial aortic coarctation: a rare cause of refractory hypertension in the elderly: a case report.Medicine. 94-4, pp.e467. ISSN 1536-5964.
Gomez-Huelgas R, Lopez-Carmona MD, Jansen-Chaparro S, Sobrino B, Chaves M, Martin-Gallardo P, Garcia-Fernandez C, Bernal-Lopez MR. Assessment of an educational intervention in the management of non-critical inpatient glycemic control. Acta Diabetol. 2014;51(3):377-83. doi: 10.1007/s00592-013-0520-8.
Scientific reference data
María Dolores López Carmona
Scientific signature: Lopez-Carmona MD
ORCID: 0000-0001-9333-076X
